Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 11:19 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1009–1032 of 7,628 matching trials from the live ClinicalTrials.gov search.

Filters: Jacksonville, Florida Clear all

Conditions: Pulmonary Hypertension, Interstitial Lung Disease, Combined Pulmonary Fibrosis and Emphysema
Interventions: Inhaled Treprostinil, Placebo; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 326 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 96
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 71 more

Conditions: Melanoma
Interventions: Minimally invasive inguinal lymph node dissection; Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 11
States / cities: Scottsdale, Arizona • Santa Monica, California • Jacksonville, Florida + 8 more

Conditions: Solid Tumours Harboring NRG1 Fusion, NSCLC Harboring NRG1 Fusion, Pancreatic Cancer Harboring NRG1 Fusion, NRG1 Fusion
Interventions: zenocutuzumab (MCLA-128); Drug
Lead sponsor: Partner Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2026
U.S. locations: 26
States / cities: Phoenix, Arizona • Cerritos, California • Irvine, California + 21 more

Conditions: Obesity
Interventions: Semaglutide, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Jacksonville, Florida • Rochester, Minnesota

Conditions: Peripheral Arterial Disease, Lower Extremity Arterial Disease
Interventions: EverFlex™ Self-Expanding Peripheral Stent System; Device
Lead sponsor: Medtronic Endovascular; Industry
Eligibility: 18 Years and older
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 23
States / cities: Phoenix, Arizona • Modesto, California • Sacramento, California + 20 more

Conditions: Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Low Grade Glioma, Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Glioma, Recurrent Hepatoblastoma, Recurrent Hodgkin Lymphoma, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Glioma, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Primary Central Nervous System Neoplasm, Recurrent Rhabdoid Tumor, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Refractory Hodgkin Lymphoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Glioma, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Rhabdoid Tumor, Refractory Soft Tissue Sarcoma, Rhabdoid Tumor, Stage III Soft Tissue Sarcoma AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7, Wilms Tumor
Interventions: Tazemetostat; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Months to 21 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 115
States / cities: Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 91 more

Conditions: Hyperlipidemia
Interventions: Bococizumab (PF-04950615; RN316), Placebo; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 2,139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 155
States / cities: Athens, Alabama • Birmingham, Alabama • Huntsville, Alabama + 115 more

Conditions: Iliac Artery Stenosis
Interventions: Misago® RX Self-expanding Peripheral Stent; Device
Lead sponsor: Terumo Medical Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 9
States / cities: Thornton, Colorado • Gainesville, Florida • Jacksonville, Florida + 6 more

Conditions: Eosinophilic Gastritis, Eosinophilic Duodenitis
Interventions: lirentelimab (AK002), Placebo; Drug · Other
Lead sponsor: Allakos Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 181 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 60
States / cities: Birmingham, Alabama • Huntsville, Alabama • Gilbert, Arizona + 54 more

Conditions: Emphysema
Interventions: Spiration Valve System, Medical Management; Device · Other
Lead sponsor: Olympus Corporation of the Americas; Industry
Eligibility: 40 Years and older
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 32
States / cities: Fort Smith, Arkansas • Riverside, California • San Diego, California + 28 more

Conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions: Cyclophosphamide, Laboratory Biomarker Analysis, Pharmacological Study, Quality-of-Life Assessment, Smac Mimetic LCL161; Drug · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 3
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: Melanoma, Advanced Melanoma, Metastatic Melanoma, Unresectable Melanoma
Interventions: CMP-001, Nivolumab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 25
States / cities: Phoenix, Arizona • Duarte, California • Los Angeles, California + 21 more

Conditions: Major Depressive Disorder
Interventions: Pexacerfont, Escitalopram, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 271 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 45
States / cities: Springdale, Arkansas • Orange, California • Upland, California + 39 more

Conditions: Crohn's Disease
Interventions: Dehydroepiandrosterone [DHEA]; Drug
Lead sponsor: Inflabloc Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 29
States / cities: Huntsville, Alabama • Anaheim, California • San Diego, California + 25 more

Conditions: Angina Pectoris
Interventions: pVGI.1(VEGF2); Genetic
Lead sponsor: Corautus Genetics; Industry
Eligibility: 18 Years and older
Enrollment: 404 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 35
States / cities: Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 27 more

Conditions: Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma
Interventions: VG161, Nivolumab Injection [Opdivo]; Drug
Lead sponsor: Virogin Biotech Canada Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 3
States / cities: Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: Lymphoma, Non-Hodgkin
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 21,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2031
U.S. locations: 12
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Miami, Florida + 7 more

Conditions: Heart Disease, Ischemic Heart Disease
Interventions: apadenoson; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 77
States / cities: Birmingham, Alabama • Huntsville, Alabama • North Little Rock, Arkansas + 69 more

Conditions: Acute Coronary Syndrome, High Bleeding Risk
Interventions: BioFreedom™ Drug Coated Coronary Stent System, Antiplatelet Drug; Device · Drug
Lead sponsor: Biosensors Europe SA; Industry
Eligibility: Not listed
Enrollment: 1,203 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 39
States / cities: Huntsville, Alabama • Hot Springs, Arkansas • La Jolla, California + 34 more

Conditions: Hepatitis C, Chronic
Interventions: ribavirin [Copegus], peginterferon alfa-2a (PEG-IFN alfa-2a) [Pegasys]; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 188 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 24
States / cities: La Jolla, California • Long Beach, California • San Diego, California + 20 more

Conditions: Open-angle Glaucoma, Ocular Hypertension
Interventions: AGN-193408 SR, Lumigan, Sham Administration, Lumigan Vehicle; Drug · Other
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 42
States / cities: Sun City, Arizona • Glendale, California • Inglewood, California + 38 more

Conditions: Lyme Disease
Interventions: mRNA-1975, mRNA-1982, Placebo; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 807 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 20
States / cities: Milford, Connecticut • Stamford, Connecticut • Waterbury, Connecticut + 17 more

Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Early Stage HER2+ Breast Cancer
Interventions: Trastuzumab (Herceptin), Pertuzumab, Echocardiography, Multigated Acquisition Scan, Mammography, Ultrasound, Magnetic Resonance Imaging, Biospecimen Collection, Questionnaire Administration; Biological · Procedure · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 1,524 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2037
U.S. locations: 698
States / cities: Phoenix, Arizona • Fort Smith, Arkansas • Jonesboro, Arkansas + 537 more

Conditions: Breast Cancer
Interventions: cyclophosphamide, Taxotere, Adriamycin; Drug
Lead sponsor: NSABP Foundation Inc; Network
Eligibility: 18 Years and older · Female only
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2002
U.S. locations: 152
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 120 more

Search by objective public record fields.

Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE

Minimally Invasive Groin Dissection for Melanoma

A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)

A Study of a Novel Precision Medicine Approach For Obesity

EverFlex Post Approval Study

Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)

Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events

Misago® RX Self-expanding Peripheral Stent for Common and/or External Iliac Artery

A Study to Assess AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis)

Evaluation of the Spiration® Valve System for Emphysema to Improve Lung Function

SMAC Mimetic LCL161 Alone or With Cyclophosphamide in Treating Patients With Relapsed or Refractory Multiple Myeloma

CMP-001 in Combination With Nivolumab in Subjects With Advanced Melanoma

Study of BMS-562086 in the Treatment of Outpatients With Major Depressive Disorder

An Efficacy and Safety Evaluation of Inflabloc Cap in the Treatment of Patients With Crohn's Disease

To Find the Best Dose of pVGI.1(VEGF2) to Benefit Angina Patients When Given With an Experimental Injection Catheter

An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Evaluation of Lymphoma Prognosis and Survivorship in Recently Diagnosed Patients, LEO Study

A Study to Examine MPI SPECT Imaging With BMS068645 and Adenosine Compared to Coronary Angiography

LEADERS FREE II: BioFreedom™ Pivotal Study

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C Infection (CHC).

AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension

A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

Combination Chemotherapy in Treating Women With Stage IIIB or Stage IV Breast Cancer